ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Expands Nexavar Indication To Include Thyroid Cancer

December 27, 2013

In Brief: NCFA Offers Grants For Research On Impact Of DRGs; ACCC Leaders Dispute HCFA Chief

March 8, 1985

DCT Board Approves Continuing Neutron Trials Pas 1989 Expiration, With New Funding Plan

June 10, 1988

HPV-Positive Women Over 30 Should Be Retested Within Two Years

September 30, 2011

CCOPs Payline Set In Low 220s Fr Now; 45 To Be Funded

May 15, 1987

NCI Objections Delay GAO Report On Cancer Control

March 7, 1980